[Adjuvant treatments of early breast cancer without lymph node involvement].
Lymph node status remains the most important prognostic factor in breast cancer. However, only 70% of the node negative breast cancer patients are alive at 10 years. Several randomized trials have shown that systemic adjuvant therapy, either chemo or hormonotherapy, increases survival in these patients. A recent meta-analysis confirms these findings. In 1992, a consensus conference recommended no therapy in low risk patients (tumor size less than 1 cm), tamoxifen in good risk patients (tumor less than 2 cm, oestrogen or progesterone receptors positive, well differentiated) and chemotherapy in premenopausal or hormonotherapy in postmenopausal high risk patients (receptor-negative less than 1 cm tumor or high pathological grade).
Krulik
M
M
Service de médecine interne-oncologie, hôpital Saint-Antoine, Paris, France.
D001943:Breast Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D011379:Prognosis; D012307:Risk Factors
Les traitements adjuvants du cancer du sein précoce sans atteinte ganglionnaire.